Clinical Trial Update: Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD6244 with docetaxel for second-line non-small cell lung cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD6244 (selumetinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | Phase 2 | Status: COMPLETED | Results posted: 2017-07-19